PRTA

Prothena Corporation plc

PRTA.US prothena.com + Research + Basket
CIK 0001559053
Employees 67
Phone 353 1 236 2500
Fiscal year end December
IPO Dec 21, 2012
Address 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
8.47
-0.41 (-4.62%)
USD · NASDAQ
52-week range
7.73
11.80
Trading at 18% of the 52-week range
Market Cap
455.87M
P/E Ratio
0.00
Forward P/E
10.63
Book Value
5.54
Div. Yield
N/A
% Institutions
93.26%
% Insiders
22.85%

1 Year

-19.2%

3 Year

-76.8%

10 Year

-82.3%
Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Actions

Add an action for PRTA.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Gene G. Kinney Ph.D. President, CEO & Director 1969
Mr. Tran B. Nguyen M.B.A. Chief Financial Officer 1974
Mr. Brandon S. Smith Chief Operating Officer 1975
Dr. Wagner M. Zago Ph.D. Chief Scientific Officer 1973
Ms. Karin L. Walker CPA Chief Accounting Officer & Controller 1963
Mr. Mark C. Johnson C.F.A. Vice President of Investor Relations NA
Mr. Michael J. Isaacs General Counsel & Corporate Secretary NA
Phillip Dolan Sr. Director & Head of Exploratory Research NA
Ms. Annie Evans Kingston Chief Strategy Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Jan 14, 2025 William P Scully N/A Purchase 100.00K $12.79 $1.28M SEC
Dec 31, 2024 William P Scully N/A Purchase 32.00K $13.01 $416.32K SEC
Dec 20, 2024 William P Scully N/A Purchase 2.00K $15.91 $31.82K SEC
Dec 18, 2024 William P Scully N/A Purchase 73.44K $13.93 $1.02M SEC
Jan 24, 2024 Karin L. Walker N/A Sale 5.00K $34.00 $170.00K SEC
Dec 20, 2023 Karin L. Walker N/A Sale 5.00K $37.19 $185.95K SEC
Nov 30, 2023 Karin L. Walker N/A Sale 5.00K $34.00 $170.00K SEC
Oct 25, 2023 Karin L. Walker N/A Sale 5.00K $41.04 $205.20K SEC
Oct 11, 2023 Brandon S. Smith N/A Sale 4.00K $46.75 $187.00K SEC
Oct 04, 2023 Carol D. Karp N/A Sale 5.00K $46.62 $233.10K SEC
Sep 27, 2023 Michael J. Malecek N/A Sale 5.00K $47.38 $236.90K SEC
Sep 19, 2023 Karin L. Walker N/A Sale 5.00K $52.36 $261.80K SEC
Sep 13, 2023 Brandon S. Smith N/A Sale 4.00K $55.49 $221.96K SEC
Sep 13, 2023 Hideki Garren N/A Sale 2.00K $55.48 $110.96K SEC
Sep 06, 2023 Carol D. Karp N/A Sale 5.00K $54.76 $273.80K SEC
Aug 30, 2023 Michael J. Malecek N/A Sale 5.00K $55.01 $275.05K SEC
Aug 18, 2023 Karin L. Walker N/A Sale 5.00K $57.18 $285.90K SEC
Aug 16, 2023 Hideki Garren N/A Sale 2.00K $58.74 $117.48K SEC
Aug 16, 2023 Brandon S. Smith N/A Sale 4.00K $58.71 $234.84K SEC
Aug 02, 2023 Wagner M. Zago N/A Sale 4.00K $67.05 $268.20K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 7.20M Jun 30, 2026 14.02% $0.00 -4.66%
Rubric Capital Management LP 5.00M Jun 30, 2026 9.74% $0.45 0.00%
BlackRock Inc 4.87M Jun 30, 2026 9.48% $0.00 4.82%
State Street Corp 2.39M Jun 30, 2026 4.66% $0.00 23.47%
Acadian Asset Management LLC 2.01M Jun 30, 2026 3.92% $0.02 29.92%
Vanguard Portfolio Management, LLC 1.65M Jun 30, 2026 3.22% $0.00 14.20%
D. E. Shaw & Co LP 1.61M Jun 30, 2026 3.14% $0.01 -8.61%
ADAR1 Capital Management LLC 1.55M Jun 30, 2026 3.03% $0.70 -1.70%
Two Sigma Investments LLC 1.26M Jun 30, 2026 2.46% $0.01 4.89%
Palo Alto Investors, LLC 1.14M Jun 30, 2026 2.23% $1.55 -5.41%
Geode Capital Management, LLC 1.13M Jun 30, 2026 2.19% $0.00 2.52%
Federated Hermes Inc 1.08M Jun 30, 2026 2.11% $0.02 2.32%
Morgan Stanley - Brokerage Accounts 995.35K Jun 30, 2026 1.94% $0.00 -19.11%
The Goldman Sachs Group Inc 979.73K Jun 30, 2026 1.91% $0.00 19.64%
Jacobs Levy Equity Management, Inc. 965.99K Jun 30, 2026 1.88% $0.03 -0.62%
Dimensional Fund Advisors, Inc. 905.65K Jun 30, 2026 1.76% $0.00 15.72%
Qube Research & Technologies 791.17K Jun 30, 2026 1.54% $0.01 28.73%
Renaissance Technologies Corp 697.62K Jun 30, 2026 1.36% $0.01 14.83%
Man Group PLC 678.12K Jun 30, 2026 1.32% $0.01 77.72%
Mariner Wealth Advisors LLC 625.10K Jun 30, 2026 1.22% $0.01 11.01%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Company Fund 2.19M 4.26% ▼ 1.94% Aug 31, 2026
2 iShares Russell 2000 ETF 1.12M 2.18% ▼ 1.14% Sep 30, 2026
3 State Street® SPDR® S&P® Biotech ETF 910.08K 1.77% ▼ 1.88% Sep 30, 2026
4 Vanguard Explorer Inv 757.20K 1.48% ▲ 22.68% Jun 30, 2026
5 Fidelity Series Growth Company 723.71K 1.41% ▼ 1.94% Aug 31, 2026
6 Fidelity Small Cap Index 485.99K 0.95% ▲ 0.96% Jul 31, 2026
7 Fidelity Select Biotechnology 472.62K 0.92% ▼ 1.93% Aug 31, 2026
8 Fidelity Growth Company K6 406.94K 0.79% ▼ 1.95% Aug 31, 2026
9 Federated Hermes MDT Small Cap Core IS 394.35K 0.77% ▲ 0.00% Jun 30, 2026
10 iShares Biotechnology ETF 349.94K 0.68% ▼ 0.75% Sep 30, 2026

Financial Highlights

▼
Market Cap: $455.87M
EBITDA: $-59.04M
PEG Ratio: $0.80
Book Value: $5.54
Earnings/Share: $-0.82
Profit Margin: -80.68%
Operating Margin: -1,850.20%
ROA (TTM): -10.67%
ROE (TTM): -14.40%
Revenue (TTM): $54.53M
Revenue/Share (TTM): $1.02
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -77.10%

Valuation Metrics

Enterprise Value: $186.48M
Trailing P/E: 0.00
Forward P/E: 10.63

Shares Statistics

Shares Outstanding: 51.34M
Shares Float: 33.97M
% Insiders: 22.85%
% Institutions: 93.26%
Shares Short: 7.94M
Shares Short (Prior Month): 8.01M
Short Ratio: 13.61
Short % Float: 18.63%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$9.68M
Cost of Goods Sold
adjust
$-3.70M
Gross Profit
subtotal
$5.98M
SG&A
adjust
$-59.39M
R&D
adjust
$-134.85M
Operating Income
subtotal
$-184.56M
Other / Non-Operating Items
adjust
$-59.53M
Net Income
subtotal
$-244.09M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PRTA.US!